Grow Therapy Revenue, Valuation, Funding & Investors

Grow Therapy is valued at $3B as of March 2026.

Last Grow Therapy valuation

$3B

Series D · Mar 2026

Last Grow Therapy funding round

$150M

Series D · Mar 2026

Grow Therapy revenue

$1B

Series C · Apr 2024

Key investors in Grow Therapy

  • SignalFire
  • TCV
  • Transformation Capital
  • Sequoia Capital
  • Goldman Sachs
  • Menlo Ventures

Grow Therapy Overview

About Grow Therapy

Grow Therapy is a New York-headquartered online platform connecting clients with licensed mental health providers across all 50 U.S. states. It handles credentialing, billing, and insurance claims for in-network therapists, integrating with Aetna, Cigna, Medicare, Medicaid, and UnitedHealthcare among 100-plus payers. The service delivers matched referrals, business tools, peer communities, and continuing education events to independent practitioners. Supporting thousands of therapists serving over 1 million clients, Grow Therapy raised $178 million from investors including Sequoia Capital and Goldman Sachs Alternatives.


Founded

2020

HQ

United StatesNew York City, NY

Status

Privately held

Customer focus

B2C & B2B

Revenue model

Services, Commission, Subscription

Revenue

$1B (Apr 2024)

Valuation

$3B (Mar 2026)

Grow Therapy Valuation

Grow Therapy is currently valued at $3B, based on its Series D in March 2026.

The $150M round was led by Goldman Sachs Growth Equity and TCV, with participation from Menlo Ventures, SignalFire, Sequoia Capital, BCI and Transformation Capital.

Grow Therapy's valuation has moved from $3B at its Series C in April 2024 to $3B in March 2026, across 2 priced rounds.

Grow Therapy valuation by funding round

Revenue multiple
Grow Therapy valuation by funding round
DateStageValuationRevenue Multiple
Mar 2026Series D$3B-
Apr 2024Series C$3B3.0x

Grow Therapy Revenue

Grow Therapy's latest recorded revenue is $1B, as of its Series C in April 2024. At a $3B valuation, that implies a 3.0x revenue multiple.

Grow Therapy revenue by funding round

Grow Therapy revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Apr 2024$1B$3B3.0xSeries C

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Grow Therapy Funding History

Grow Therapy has raised a total of $298M across 4 funding rounds.

Grow Therapy's first fundraising round was a $15M Series A in September 2021. The most recent completed round was a $150M Series D in March 2026.

Grow Therapy funding rounds

Grow Therapy funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Mar 2026Series DGoldman Sachs Growth Equity (lead); TCV (lead); Menlo Ventures; SignalFire; Sequoia Capital; BCI; Transformation Capital$150M$3B-
Apr 2024Series CSequoia Capital (lead); Plus Capital; Lauren Holiday; SignalFire; Joe Burrow; Goldman Sachs; TCV; Lily Collins; Jrue Holiday; Anna Kendrick; Dak Prescott; Transformation Capital$88M$3BGrow Therapy is a mental health platform founded in 2020 that connects patients with therapists and psychiatrists through insurance-covered services, aiming to reduce barriers like long waitlists and insurance gaps by integrating with insurers, employers, health systems, and primary care providers. The company raised $150 million in a Series D round in early March 2026, led by TCV and Goldman Sachs Alternatives (Growth Equity), with participation from new investors BCI and Menlo Ventures; existing investors Sequoia Capital, SignalFire, and Transformation Capital did not join this round despite earlier indications. Bloomberg reported a post-money valuation of $3 billion for this round, while the company confirmed approximately $1 billion in annual revenue. Since its prior $88 million Series C in April 2024 led by Goldman Sachs Alternatives, Grow Therapy has scaled significantly, facilitating seven million visits in 2025 alone (10 million lifetime total) for over two million people, achieving an 85 Net Promoter Score with 90% strongly recommending the service. The company covers 220 million lives through insurance and EAP partnerships, recently announcing a deal with Circle Medical operating in 24 states in-person and 32 digitally. Funds will expand platform capabilities, including AI integration such as the acquisition of AI scribe Tenor and launch of a patient-facing app with AI-assisted journaling to reduce provider administrative burdens. Grow Therapy's growth reflects investor confidence in its execution amid a rationalized funding market post-COVID boom, positioning it as a leader in digital mental health alongside peers like Headway and Alma (recently acquired by Spring Health). Total funding raised now stands at $328 million, with plans to further integrate mental health into primary care and employer benefits for broader accessibility.
Sep 2022Series BTCV (lead); Transformation Capital (lead); SignalFire; Silicon Valley Bank$45M--
Sep 2021Series ASignalFire (lead); Cold Start Ventures; CoFound Partners; What If Ventures$15M-Grow Therapy raised a $15 million Series A round in 2021 with participation from SignalFire and other investors including CoFound Partners, Cold Start Ventures, and What If Ventures. SignalFire served as the lead investor for this round.[user query] The funding supported the early-stage mental health platform connecting patients with licensed providers for therapy and psychiatric care via virtual and in-person services. Subsequent rounds included a $75 million Series B in 2022 and an $88 million Series C in 2024.

Who has invested in Grow Therapy?

19 investors have backed Grow Therapy across its funding rounds, including SignalFire, TCV, Transformation Capital, Sequoia Capital, Goldman Sachs and Menlo Ventures.

Lead investors include Goldman Sachs Growth Equity, TCV, Sequoia Capital, Transformation Capital and SignalFire.


Grow Therapy Investors

Investors in Grow Therapy by funding rounds participated
InvestorHQRoundsRoleFirst check
SignalFireUnited StatesSan Francisco, CA4LeadSep 2021
TCVUnited StatesSan Francisco, CA3LeadSep 2022
Transformation CapitalUnited StatesBoston, MA3LeadSep 2022
Sequoia CapitalUnited StatesSan Francisco, CA2LeadApr 2024
Cold Start VenturesUnited StatesNew York City, NY1ParticipantSep 2021
Plus CapitalUnited StatesLos Angeles, CA1ParticipantApr 2024
Menlo VenturesUnited StatesSan Francisco, CA1ParticipantMar 2026
Lauren HolidayUnited StatesIndianapolis, IN1ParticipantApr 2024
Joe BurrowUnited StatesAmes, IA1ParticipantApr 2024
Goldman SachsUnited StatesNew York City, NY1ParticipantApr 2024
CoFound PartnersUnited StatesNew York City, NY1ParticipantSep 2021
Lily Collins--1ParticipantApr 2024
Jrue HolidayUnited StatesLos Angeles, CA1ParticipantApr 2024

This data is available for Pro users. Sign up to see all 19 Grow Therapy investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Grow Therapy

Grow Therapy has acquired 2 companies to date.

Last acquisition by Grow Therapy was on February 10th 2026. Grow Therapy acquired Tenor Therapy for undisclosed valuation.


Latest Acquisitions by Grow Therapy

Tenor Therapy
Neosync
Description
Tenor Therapy is a HIPAA-compliant AI platform generating clinical therapy notes and streamlining administrative paperwork for mental health professionals.
Neosync is an open-source data synchronization and anonymization platform. The Portland-headquartered project enables real-time database replication with privacy-preserving transformations for development and testing environments. Launched in 2023, Neosync integrates with PostgreSQL, MySQL, and Snowflake, supporting enterprises in compliant data pipelines.
HQ CountryUnited StatesUnited States
HQ City
-
San Francisco, CA
Deal Date10 Feb 202625 Sep 2025
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Grow Therapy acquisitions and their M&A valuation multiples.

Start Free Trial

Grow Therapy Competitors

Grow Therapy competitors include listed companies like Doximity and Guiyang Longmaster, and private ones like eMed, Cityblock Health, Doctolib and Clarify Health Solutions.

Public and private companies comparable to Grow Therapy
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
eMedUnited StatesMiami, FLPrivate--$2B-
DoximityUnited StatesUnited StatesPublicly listed$645M$229M$4.7B6.2x
Cityblock HealthUnited StatesNew York City, NYPrivate--$5.7B-
DoctolibFranceParisPrivate$400M-$6.4B16.0x
Clarify Health SolutionsUnited StatesSan Francisco, CAPrivate--$1.4B-
Guiyang LongmasterChinaChinaPublicly listed$44M$5M$482M-

Grow Therapy Public Comps

Grow Therapy is still privately-owned, but its public comps include Privia Health, Tieto, Schrödinger, CCC Intelligent Solutions, Compass Pathways, Qingdao Baheal Medical, Ping An Healthcare, JMDC, Omnicell and ACADIA Pharmaceuticals.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Privia Health$2.1B$44M1.0x0.9x50.2x15.3x
Tieto$2.1B$186M1.3x1.4x15.2x7.9x
Schrödinger$256M($96M)7.6x7.9x(20.3x)(14.0x)
CCC Intelligent Solutions$1.1B$238M4.8x4.5x21.5x10.8x
Compass Pathways-($293M)--(5.8x)(8.4x)
Qingdao Baheal Medical$1.1B$139M1.9x1.9x15.1x16.8x
Ping An Healthcare$815M$52M0.9x0.9x13.4x16.9x
JMDC$324M$88M5.0x4.6x18.4x17.9x

This data is available for Pro users. Sign up to see all Grow Therapy competitors and their valuation data.

Start Free Trial

Common questions about Grow Therapy

When was Grow Therapy founded?Grow Therapy was founded in 2020.
Where is Grow Therapy headquartered?Grow Therapy is headquartered in New York City, NY, United States.
Is Grow Therapy publicly listed?No, Grow Therapy is a private, VC-backed company.
What is Grow Therapy's valuation?Grow Therapy was last valued at $3B in its Series D in March 2026.
How much funding has Grow Therapy raised?Grow Therapy has raised $298M across 4 funding rounds.
What was Grow Therapy's last funding round?Grow Therapy's last funding round was a $150M Series D in March 2026, led by Goldman Sachs Growth Equity and TCV.
Who are Grow Therapy's investors?Grow Therapy's investors include SignalFire, TCV, Transformation Capital, Sequoia Capital, Cold Start Ventures, Plus Capital, Menlo Ventures, Lauren Holiday, Joe Burrow, Goldman Sachs and 9 others.
What is Grow Therapy's revenue?Grow Therapy's latest recorded revenue is $1B (April 2024).
What is Grow Therapy's revenue multiple?Grow Therapy's latest valuation implies a 3.0x revenue multiple ($3B valuation on $1B of revenue).
Which companies are comparable to Grow Therapy?Companies comparable to Grow Therapy include eMed, Doximity, Cityblock Health, Doctolib, Clarify Health Solutions and Guiyang Longmaster.
How many companies has Grow Therapy acquired?Grow Therapy has acquired 2 companies, including Tenor Therapy and Neosync.

See companies similar to Grow Therapy

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial